Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277350 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
A Phase 1 study of E Coli Infections and Bloodstream Infection, sponsored by SNIPR Biome Aps..
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05277350: Completed Phase 1 study of E Coli Infections and Bloodstream Infection, sponsored by SNIPR Biome Aps..
NCT05277350 is a Phase 1 study of E Coli Infections and Bloodstream Infection that has completed, run by SNIPR Biome Aps.. The registered enrollment target is 36 participants, below the 1,188-participant average among 4 other E Coli Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277350, a Phase 1 study of E Coli Infections and Bloodstream Infection, has completed, sponsored by SNIPR Biome Aps..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SNIPR001
Study Locations (1)
Ohio
- Medpace Clinical Pharmacology - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
What the finished NCT05277350 record still lists
NCT05277350 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,188-participant average among 4 other E Coli Infections trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with E Coli Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05277350 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05277350 about?
NCT05277350 is a clinical study titled "A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects". This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
What is the current status of trial NCT05277350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-03-24. Estimated completion is 2023-05-01.
What conditions does trial NCT05277350 study?
This clinical trial studies the following conditions: E Coli Infections, Bloodstream Infection.
What interventions are being tested in trial NCT05277350?
The interventions under investigation include: Placebo (DRUG), SNIPR001 (DRUG).
Who is sponsoring clinical trial NCT05277350?
This trial is sponsored by SNIPR Biome Aps., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277350 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for E Coli Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
RECRUITING · Phase 1
-
Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol
COMPLETED
-
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
COMPLETED
-
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI